Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice

[1]  R. Siebert,et al.  Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33) , 2009, Leukemia.

[2]  John Calvin Reed,et al.  Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. , 2009, Blood.

[3]  J. Carpten,et al.  Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. , 2009, Cancer research.

[4]  T. Mak,et al.  Activation of noncanonical NF-κB requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2, TRAF3 and the kinase NIK , 2008, Nature Immunology.

[5]  J. Keats,et al.  Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling , 2008, Nature Immunology.

[6]  F. Caligaris‐cappio,et al.  Autoimmune disorders and lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  F. Mackay,et al.  TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. , 2008, Immunity.

[8]  G. Bishop,et al.  Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. , 2007, Immunity.

[9]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[10]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[11]  Yang Yang,et al.  Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-κB signal pathways , 2005, Molecular Cancer Therapeutics.

[12]  S. Tangye,et al.  The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. , 2004, Current opinion in pharmacology.

[13]  Suzanne Cory,et al.  The Bcl-2 family: roles in cell survival and oncogenesis , 2003, Oncogene.

[14]  James R. Burke,et al.  BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice* , 2003, The Journal of Biological Chemistry.

[15]  K. McIntyre,et al.  BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. , 2003, The Journal of biological chemistry.

[16]  N. Harris,et al.  Bethesda proposals for classification of lymphoid neoplasms in mice. , 2002, Blood.